Kurs
-1,69%
Prenumeration
Kalender
Est. tid* | ||
2025-02-26 | - | Bokslutskommuniké 2024 |
2024-11-29 | - | Kvartalsrapport 2024-Q3 |
2024-10-29 | - | Extra Bolagsstämma 2024 |
2024-08-22 | - | Kvartalsrapport 2024-Q2 |
2024-05-30 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
2024-05-29 | - | Årsstämma |
2024-05-28 | - | Kvartalsrapport 2024-Q1 |
2024-02-29 | - | Bokslutskommuniké 2023 |
2024-01-31 | - | Split PMDS 128:1 |
2023-12-29 | - | Extra Bolagsstämma 2023 |
2023-11-28 | - | Kvartalsrapport 2023-Q3 |
2023-08-30 | - | Kvartalsrapport 2023-Q2 |
2023-06-27 | - | Årsstämma |
2023-05-24 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
2023-05-23 | - | Kvartalsrapport 2023-Q1 |
2023-02-28 | - | Bokslutskommuniké 2022 |
2022-11-29 | - | Kvartalsrapport 2022-Q3 |
2022-08-30 | - | Kvartalsrapport 2022-Q2 |
2022-05-19 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
2022-05-17 | - | Årsstämma |
2022-05-17 | - | Kvartalsrapport 2022-Q1 |
2022-02-16 | - | Bokslutskommuniké 2021 |
2021-11-23 | - | Kvartalsrapport 2021-Q3 |
2021-08-24 | - | Kvartalsrapport 2021-Q2 |
2021-05-28 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
2021-05-27 | - | Årsstämma |
2021-05-27 | - | Extra Bolagsstämma 2021 |
2021-05-27 | - | Kvartalsrapport 2021-Q1 |
2021-02-23 | - | Bokslutskommuniké 2020 |
2020-11-24 | - | Kvartalsrapport 2020-Q3 |
2020-08-25 | - | Kvartalsrapport 2020-Q2 |
2020-05-27 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
2020-05-26 | - | Årsstämma |
2020-05-26 | - | Kvartalsrapport 2020-Q1 |
2020-02-18 | - | Bokslutskommuniké 2019 |
2019-11-22 | - | Kvartalsrapport 2019-Q3 |
2019-10-22 | - | Extra Bolagsstämma 2019 |
2019-08-27 | - | Kvartalsrapport 2019-Q2 |
2019-05-22 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
2019-05-21 | - | Årsstämma |
2019-05-21 | - | Kvartalsrapport 2019-Q1 |
2019-02-26 | - | Bokslutskommuniké 2018 |
2018-11-23 | - | Kvartalsrapport 2018-Q3 |
2018-08-20 | - | Kvartalsrapport 2018-Q2 |
2018-05-17 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
2018-05-16 | - | Årsstämma |
2018-05-16 | - | Kvartalsrapport 2018-Q1 |
2018-02-06 | - | Bokslutskommuniké 2017 |
2017-11-21 | - | Kvartalsrapport 2017-Q3 |
2017-08-30 | - | Kvartalsrapport 2017-Q2 |
Beskrivning
Land | Sverige |
---|---|
Sektor | Hälsovård |
Industri | Bioteknik |
STOCKHOLM, 17 August 2021 – Promore Pharma AB (publ) publishes its Q2 report for 2021 on 24 August 2021 aprox. at 1.30 PM (CET).
The same day at 4.30 PM (CET), the company will host a webcast telephone conference, with President and CEO Jonas Ekblom and CFO Erik Magnusson. After the presentation there will be a Q&A session. The conference call will be held in English and can be accessed via computer, tablet, or telephone.
The number of attendees is limited, please register for the conference in advance on the following link:
https://attendee.gotowebinar.com/register/3924236581330356749
The conference call will be recorded and made available on the company´s website after the call, and on Västra Hamnen Corporate Finance Youtube channel.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma’s two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.